If You Like Johnson & Johnson And Abbott Labs, Then You Should Consider Atrion Corporation
Doug Van Cuyk - at Seeking Alpha - Mon Feb 02, 11:32AM CST
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), ATRI: 332.77 (-2.85)
Nasdaq stocks posting largest volume increases
AP - Tue Jan 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ATRI: 332.77 (-2.85), BRID: 7.55 (-0.04), ASBB: 19.90 (+0.05), WVFC: 11.02 (-0.45), CALI: 1.35 (+0.06), SFST: 17.20 (-0.42), WBB: 16.13 (+0.08), ANTH: 3.84 (+0.06), ANAT: 104.90 (-0.10), BTA: 11.32 (-0.07), FBMS: 14.69 (+0.31), ATHX: 2.12 (unch), STXS: 2.27 (+0.13), PZZI: 7.94 (+0.08)
11 Best Mid-Cap Health Care Stocks Worth Targeting for 2015
at The Street - Fri Jan 02, 1:43PM CST
Which mid-cap health care companies should you target for the best returns? Click through to see which stocks are top-rated.
ACHC: 63.20 (-0.45), SIRO: 91.06 (+0.18), WST: 51.35 (+0.57), USPH: 41.08 (+0.07), ATRI: 332.77 (-2.85), STE: 65.50 (-0.35), GB: 50.86 (+0.20), TFX: 112.07 (+0.47), ICLR: 60.01 (+0.38), CMN: 44.28 (+1.09), UTMD: 58.02 (-0.40)
Suggesting An Entry Point For Atrion
Doug Van Cuyk - at Seeking Alpha - Tue Dec 30, 11:34AM CST
ATRI: 332.77 (-2.85)
Dividend Contenders, Future Champions Or Future Failures: Part 9
Stan Stafford - at Seeking Alpha - Thu Dec 11, 8:26PM CST
WST: 51.35 (+0.57), ATRI: 332.77 (-2.85), MLAB: 73.79 (-1.37)
Atrion's board reports USD0.75 per share dividend
M2 - Mon Nov 17, 6:19AM CST
The board of directors of Atrion (NASDAQ:ATRI), a medical applications company, on Friday declared a quarterly dividend of USD0.75 per share on the company's outstanding shares of its common stock.
ATRI: 332.77 (-2.85)
Atrion declares $0.75 dividend
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 10:22AM CST
ATRI: 332.77 (-2.85)
Atrion Corporation Declares Quarterly Cash Dividend
Marketwired - Fri Nov 14, 10:18AM CST
The Board of Directors of Atrion Corporation (NASDAQ: ATRI) today announced its quarterly dividend of 75 cents per share on its outstanding shares of Common Stock. This dividend will be payable on December 15, 2014 to stockholders of record at the close of business on December 1, 2014.
ATRI: 332.77 (-2.85)
Atrion Corporation: Not Quite A Bargain, But A Company Investors Should Keep On Their Watch List
Boring Stock Lover - at Seeking Alpha - Fri Nov 07, 7:24AM CST
ATRI: 332.77 (-2.85)
Atrion posts unchanged Q3 net income of USD7.7m
M2 - Mon Nov 03, 5:58AM CST
Medical application company Atrion (NASDAQ:ATRI) announced on Friday its diluted earnings per share of USD3.91 for third quarter of 2014.
ATRI: 332.77 (-2.85)
Atrion EPS of $3.91
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 3:38PM CDT
ATRI: 332.77 (-2.85)
Atrion Reports Third Quarter Results
Marketwired - Fri Oct 31, 3:30PM CDT
Atrion Corporation (NASDAQ: ATRI) today announced that for the third quarter of 2014 revenues totaled $36.6 million compared with $34.0 million for the same period in 2013. Operating income for the just ended quarter was $11.2 million compared to $10.7 million in the same period of 2013. On a diluted per share basis, earnings for the period increased to $3.91 as compared to $3.81 for the same quarter of last year. Net income for the third quarter of $7.7 million was the same in last year's third quarter.
ATRI: 332.77 (-2.85)
Atrion Corporation Increases Quarterly Cash Dividend by 17%
Marketwire - Wed Sep 03, 3:30PM CDT
Atrion Corporation (NASDAQ: ATRI) today announced an increase in its quarterly cash dividend from 64 cents per share to 75 cents per share. Specifically, the Board of Directors declared a quarterly dividend of 75 cents per share on its outstanding shares of Common Stock. This dividend will be payable on September 30, 2014 to stockholders of record at the close of business on September 15, 2014.
ATRI: 332.77 (-2.85)
Atrion Reports Second Quarter Results
Marketwire - Wed Aug 06, 3:30PM CDT
Atrion Corporation (NASDAQ: ATRI) today announced that for the second quarter ended June 30, 2014 revenues totaled $35.0 million compared with $32.6 million in the same period in 2013. On a diluted per share basis, earnings for the period increased to $3.48 as compared to $3.22 in the same period of last year. Net income for the second quarter totaled $6.9 million compared to $6.5 million in last year's second quarter.
ATRI: 332.77 (-2.85)
Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate (GPB) for the Treatment of Hepatic Encephalopathy in Hepatology
GlobeNewswire - Tue Feb 25, 9:25AM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that results of the Phase 2 trial of glycerol phenylbutyrate (GPB) for the treatment of hepatic encephalopathy (HE) were published in the March 2014 issue of Hepatology. The study met its primary endpoint with significantly fewer patients treated with GPB experiencing HE events as compared to patients receiving placebo.
ATRI: 332.77 (-2.85), HPTX: 26.83 (-0.05)